Cargando…

Neutralizing monoclonal antibodies against highly pathogenic coronaviruses

The pandemic of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) is a continuing worldwide threat to human health and social economy. Historically, SARS-CoV-2 follows SARS and MERS as the third coronavirus spreading across borders and contine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiang, Rong, Wang, Yang, Wang, Lili, Deng, Xiaoqian, Huo, Shanshan, Jiang, Shibo, Yu, Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716168/ https://www.ncbi.nlm.nih.gov/pubmed/35038651 http://dx.doi.org/10.1016/j.coviro.2021.12.015

Ejemplares similares

Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2
por: Yu, Fei, et al.
Publicado: (2020)

Influenza virus glycoprotein-reactive human monoclonal antibodies
por: Li, Yanbai, et al.
Publicado: (2020)

Immunotherapy of SARS based on combinations of neutralizing human monoclonal antibodies
por: Du, Lanying, et al.
Publicado: (2010)

Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection
por: Agrawal, Anurodh Shankar, et al.
Publicado: (2016)

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
por: Jiang, Shibo, et al.
Publicado: (2020)

Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses
por: Zeng, Lei-Ping, et al.
Publicado: (2017)

Potent neutralizing monoclonal antibodies against Ebola virus infection
por: Zhang, Qi, et al.
Publicado: (2016)

Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection
por: Han, Hui-Ju, et al.
Publicado: (2018)

Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections
por: Ying, Tianlei, et al.
Publicado: (2015)

A novel glycoprotein D-specific monoclonal antibody neutralizes herpes simplex virus
por: Du, Ruikun, et al.
Publicado: (2017)

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020)

Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study
por: Liao, Xuejiao, et al.
Publicado: (2022)

Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies
por: Du, Lanying, et al.
Publicado: (2010)

Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
por: Wang, Ning, et al.
Publicado: (2020)

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses: (Trends in Immunology 41, 355–359; 2020)
por: Jiang, Shibo, et al.
Publicado: (2020)

A Murine Monoclonal Antibody With Potent Neutralization Ability Against Human Adenovirus 7
por: Wang, Rong, et al.
Publicado: (2019)

Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
por: Chen, Yanjia, et al.
Publicado: (2022)

Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score
por: Johnson, Patrick W., et al.
Publicado: (2023)

A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV
por: Zhao, Guangyu, et al.
Publicado: (2013)

Novel neutralizing human monoclonal antibodies against tetanus neurotoxin
por: Minamitani, Takeharu, et al.
Publicado: (2021)

Novel monoclonal antibodies against pathogenic Leptospira
por: de Matos, Bruno Moisés, et al.
Publicado: (2014)

Potent Neutralization Ability of a Human Monoclonal Antibody Against Serotype 1 Dengue Virus
por: Lu, Jiansheng, et al.
Publicado: (2018)

Hybridoma-derived neutralizing monoclonal antibodies against Beta and Delta variants of SARS-CoV-2 in vivo
por: Wang, Qianran, et al.
Publicado: (2022)

Development of Small-Molecule Inhibitors Against Zika Virus Infection
por: Wang, Lili, et al.
Publicado: (2019)

A Human Monoclonal Antibody with Neutralizing Activity against Highly Divergent Influenza Subtypes
por: Clementi, Nicola, et al.
Publicado: (2011)

Establishment and Characterization of Monoclonal Antibodies Against SARS Coronavirus
por: Ohnishi, Kazuo
Publicado: (2007)

Generation of neutralizing and non-neutralizing monoclonal antibodies against H7N9 influenza virus
por: Yang, Fan, et al.
Publicado: (2020)

Human Monoclonal Antibodies Broadly Neutralizing against Influenza B Virus
por: Yasugi, Mayo, et al.
Publicado: (2013)

Cross-Strain Neutralizing and Protective Monoclonal Antibodies against EEEV or WEEV
por: Phelps, Amanda L., et al.
Publicado: (2021)

Monoclonal Antibodies as an Antibacterial Approach Against Bacterial Pathogens
por: Zurawski, Daniel V., et al.
Publicado: (2020)

Clonal Wars: Monoclonal Antibodies Against Infectious Pathogens
por: Tan, Joshua
Publicado: (2022)

Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2
por: Jiang, Shibo, et al.
Publicado: (2020)

Broadly neutralizing monoclonal antibodies protect against multiple tick-borne flaviviruses
por: VanBlargan, Laura A., et al.
Publicado: (2021)

Evaluation of Neutralizing Antibodies Against Highly Pathogenic Coronaviruses: A Detailed Protocol for a Rapid Evaluation of Neutralizing Antibodies Using Vesicular Stomatitis Virus Pseudovirus-Based Assay
por: Almahboub, Sarah A., et al.
Publicado: (2020)

Characterization and application of monoclonal antibodies against N protein of SARS-coronavirus
por: Shang, Bo, et al.
Publicado: (2005)

Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse(®)
por: Coughlin, Melissa, et al.
Publicado: (2007)

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
por: Tian, Xiaolong, et al.
Publicado: (2020)

Recent advances in developing small-molecule inhibitors against SARS-CoV-2
por: Xiang, Rong, et al.
Publicado: (2022)

Neutralizing Monoclonal Antibodies for Coronavirus Disease 2019 (COVID-19) in Pregnancy: A Case Series
por: Richley, Michael, et al.
Publicado: (2022)

Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies
por: Ling, Zhiyang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mn2oq9st25gck20p87n5ilc0r3